However, CRPC tumor cells often develop resistance to drugs such as enzalutamide through mechanisms including AR point mutations, AR amplification, alterations in androgen biosynthesis, and other factors (Fujita and Nonomura, 2019). The gene discussed is AR; the disease is neoplasm.